Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study von Meric-Bernstam, Funda, Bahleda, Rastislav, Hierro, Cinta, Sanson, Marc, Bridgewater, John, Arkenau, Hendrik-Tobias, Tran, Ben, Kelley, Robin Kate, Park, Joon Oh, Javle, Milind, He, Yaohua, Benhadji, Karim A, Goyal, Lipika

Volltext

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer von Prager, Gerald W., Taieb, Julien, Fakih, Marwan, Ciardiello, Fortunato, Van Cutsem, Eric, Elez, Elena, Cruz, Felipe M., Wyrwicz, Lucjan, Stroyakovskiy, Daniil, Pápai, Zsuzsanna, Poureau, Pierre-Guillaume, Liposits, Gabor, Cremolini, Chiara, Bondarenko, Igor, Modest, Dominik P., Benhadji, Karim A., Amellal, Nadia, Leger, Catherine, Vidot, Loïck, Tabernero, Josep

Volltext

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib von Giannelli, Gianluigi, Santoro, Armando, Kelley, Robin K, Gane, Ed, Paradis, Valerie, Cleverly, Ann, Smith, Claire, Estrem, Shawn T, Man, Michael, Wang, Shuaicheng, Lahn, Michael M, Raymond, Eric, Benhadji, Karim A, Faivre, Sandrine

Volltext

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma von Faivre, Sandrine, Santoro, Armando, Kelley, Robin K., Gane, Ed, Costentin, Charlotte E., Gueorguieva, Ivelina, Smith, Claire, Cleverly, Ann, Lahn, Michael M., Raymond, Eric, Benhadji, Karim A., Giannelli, Gianluigi

Volltext

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer von Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Gueorguieva, Ivelina, Lahn, Michael M. F., Blunt, Al, Benhadji, Karim A., Tabernero, Josep

Volltext

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma von Goyal, Lipika, Meric-Bernstam, Funda, Hollebecque, Antoine, Valle, Juan W., Morizane, Chigusa, Karasic, Thomas B., Abrams, Thomas A., Furuse, Junji, Kelley, Robin K., Cassier, Philippe A., Klümpen, Heinz-Josef, Chang, Heung-Moon, Chen, Li-Tzong, Tabernero, Josep, Oh, Do-Youn, Mahipal, Amit, Moehler, Markus, Mitchell, Edith P., Komatsu, Yoshito, Masuda, Kunihiro, Ahn, Daniel, Epstein, Robert S., Halim, Abdel-Baset, Fu, Yao, Salimi, Tehseen, Wacheck, Volker, He, Yaohua, Liu, Mei, Benhadji, Karim A., Bridgewater, John A.

Volltext

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer von Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Kozloff, Mark, Simionato, Francesca, Cleverly, Ann, Smith, Claire, Wang, Shuaicheng, Man, Michael, Driscoll, Kyla E., Estrem, Shawn T., Lahn, Michael M. F., Benhadji, Karim A., Tabernero, Josep

Volltext

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway von Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M

Volltext

Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial von Ghidini, Michele, Hochster, Howard, Doi, Toshihiko, Van Cutsem, Eric, Makris, Lukas, Takahashi, Osamu, Benhadji, Karim A., Mansoor, Wasat

Volltext

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer von Melisi, Davide, Oh, Do-Youn, Hollebecque, Antoine, Calvo, Emiliano, Varghese, Anna, Borazanci, Erkut, Macarulla, Teresa, Merz, Valeria, Zecchetto, Camilla, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Gandhi, Leena, Estrem, Shawn T, Benhadji, Karim A, Lanasa, Mark C, Avsar, Emin, Guba, Susan C, Garcia-Carbonero, Rocio

Volltext

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat... von Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, Driscoll, Kyla E.

Volltext

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer von Nadal, Ernest, Saleh, Mansoor, Aix, Santiago Ponce, Ochoa-de-Olza, Maria, Patel, Sandip Pravin, Antonia, Scott, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn T, Liu, Jiangang, Avsar, Emin, Lin, Wen Hong, Benhadji, Karim A, Gandhi, Leena, Guba, Susan C, Diaz, Inmaculada Ales

Volltext

Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects von Yuen, Eunice, Posada, Maria, Smith, Claire, Thorn, Katharine, Greenwood, Dale, Burgess, Michelle, A. Benhadji, Karim, Ortega, Demetrio, Chinchen, Louise, Suico, Jeffrey

Volltext

Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma von Borthakur, Gautam, Martinelli, Giovanni, Raffoux, Emmanuel, Chevallier, Patrice, Chromik, Jörg, Lithio, Andrew, Smith, Claire L., Yuen, Eunice, Oakley, Gerard Joseph, Benhadji, Karim A., DeAngelo, Daniel J.

Volltext

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer von Sullivan, Ryan J, Hollebecque, Antoine, Flaherty, Keith T, Shapiro, Geoffrey I, Rodon Ahnert, Jordi, Millward, Michael J, Zhang, Wei, Gao, Ling, Sykes, Amanda, Willard, Melinda D, Yu, Danni, Schade, Andrew E, Crowe, KrisAnne, Flynn, Daniel L, Kaufman, Michael D, Henry, James R, Peng, Sheng-Bin, Benhadji, Karim A, Conti, Ilaria, Gordon, Michael S, Tiu, Ramon V, Hong, David S

Volltext

Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib von Yamamiya, Ikuo, Hunt, Allen, Yamashita, Fumiaki, Sonnichsen, Daryl, He, Yaohua, Benhadji, Karim A.

Volltext

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma von Ikeda, Masafumi, Morimoto, Manabu, Tajimi, Masaomi, Inoue, Koichi, Benhadji, Karim A., Lahn, Michael M. F., Sakai, Daisuke

Volltext

Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS) von Shitara, Kohei, George, Ben, Taieb, Julien, Sundar, Raghav, Fakih, Marwan G., Makris, Lukas, Benhadji, Karim A., Ghidini, Michele

Volltext

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer von Ikeda, Masafumi, Takahashi, Hideaki, Kondo, Shunsuke, Lahn, Michael Mauritius Fabio, Ogasawara, Ken, Benhadji, Karim A., Fujii, Hisaki, Ueno, Hideki

Volltext

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients von Serova, Maria, Tijeras-Raballand, Annemilaï, Dos Santos, Célia, Albuquerque, Miguel, Paradis, Valerie, Neuzillet, Cindy, Benhadji, Karim A, Raymond, Eric, Faivre, Sandrine, de Gramont, Armand

Volltext